

**Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit**

By: Abdul-Aziz, MH (Abdul-Aziz, Mohd H.)^{1,2,3}; Abd Rahman, AN (Abd Rahman, Azrin N.)^{2,3}; Mat-Nor, MB (Mat-Nor, Mohd-Basri)⁴; Sulaiman, H (Sulaiman, Helm)⁵; Wallis, SC (Wallis, Steven C.)¹; Lipman, J (Lipman, Jeffrey)^{1,6}; Roberts, JA (Roberts, Jason A.)^{1,6}; Staats, CE (Staats, Christine E.)^{3,7}

[View ResearcherID and ORCID](#)

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Volume: 60 Issue: 1 Pages: 206-214

DOI: 10.1128/AAC.01543-15

Published: JAN 2016

[View Journal Information](#)

Abstract

Doripenem has been recently introduced in Malaysia and is used for severe infections in the intensive care unit. However, limited data currently exist to guide optimal dosing in this scenario. We aimed to describe the population pharmacokinetics of doripenem in Malaysian critically ill patients with sepsis and use Monte Carlo dosing simulations to develop clinically relevant dosing guidelines for these patients. In this pharmacokinetic study, 12 critically ill adult patients with sepsis receiving 500 mg of doripenem every 8 h as a 1-hour infusion were enrolled. Serial blood samples were collected on 2 different days, and population pharmacokinetic analysis was performed using a nonlinear mixed-effects modelling approach. A two-compartment linear model with between-subject and between-occasion variability on clearance was adequate in describing the data. The typical volume of distribution and clearance of doripenem in this cohort were 0.47 liters/kg and 0.14 liters/kg/h, respectively. Doripenem clearance was significantly influenced by patients' creatinine clearance (CLCR), such that a 30-ml/min increase in the estimated CLCR would increase doripenem CL by 52%. Monte Carlo dosing simulations suggested that, for pathogens with a MIC of 8 mg/liter, a dose of 1,000 mg every 8 h as a 4-h infusion is optimal for patients with a CLCR of 30 to 100 ml/min, while a dose of 2,000 mg every 8 h as a 4-h infusion is best for patients manifesting a CLCR of > 100 ml/min. Findings from this study suggest that, for doripenem usage in Malaysian critically ill patients, an alternative dosing approach may be meritorious, particularly when multidrug resistance pathogens are involved.

Keywords

KeyWords Plus: AUGMENTED RENAL CLEARANCE; BETA-LACTAM ANTIBIOTICS; ASIA-PACIFIC REGION; IN-VITRO ACTIVITY; NOSOCOMIAL PNEUMONIA; TARGET ATTAINMENT; MEROPENEM; CARBAPENEMS; PATHOGENS; PHARMACODYNAMICS

Author Information

Reprint Address: Abdul-Aziz, MH (reprint author)

[x] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia.

Reprint Address: Abdul-Aziz, MH (reprint author)

[x] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia.

Addresses:

- [x] [1] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
- [x] [2] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
- [x] [3] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
- [4] Int Islamic Univ Malaysia, Sch Med, Dept Anesthesiol & Intens Care, Kuantan, Pahang, Malaysia
- [x] [5] Univ Malaya, Fac Med, Dept Med, Infect Dis Unit, Kuala Lumpur, Malaysia
- [6] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
- [7] Australian Ctr Pharmacometr, Brisbane, Qld, Australia

E-mail Addresses: mohd.abdulaziz1@uqconnect.edu.au

Funding

Funding Agency	Grant Number
International Islamic University of Malaysia Research Endowment Grant	ED/WB 11-148-0626

[View funding text](#)

Publisher

AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA

Categories / Classification

Research Areas: Microbiology; Pharmacology & Pharmacy

Web of Science Categories: Microbiology; Pharmacology & Pharmacy

Document Information

Document Type: Article

Language: English

Accession Number: WOS:000369154600025

PubMed ID: 26482304

ISSN: 0066-4804

eISSN: 1098-6596

Journal Information

Impact Factor: Journal Citation Reports®

Other Information

ID \$ Number: DC3XZ

Cited References in Web of Science Core Collection: 53

Times Cited in Web of Science Core Collection: 0

Citation Network

0 Times Cited

53 Cited References

[View Related Records](#)

[View Citation Map](#)

[Create Citation Alert](#)

(data from Web of Science™ Core Collection)

All Times Cited Counts

0 In All Databases

0 In Web of Science Core Collection

0 In BIOSIS Citation Index

0 In Chinese Science Citation Database

0 In Data Citation Index

0 In Russian Science Citation Index

0 In ScELO Citation Index

Usage Count

Last 180 Days: 0

Since 2013: 0

[Learn more](#)

This record is from:

Web of Science™ Core Collection

Suggest a correction

If you would like to improve the quality of the data in this record, please [suggest a correction](#).

Search

Alerts

Lists

My Scopus

Back to results | 1 of 1

[Full Text](#) | [View at Publisher](#) | [CSV export](#) | [Download](#) | [Save to list](#) | [More...](#)

Antimicrobial Agents and Chemotherapy

Volume 60, Issue 1, 1 January 2016, Pages 206-214

Population pharmacokinetics of doripenem in critically ill patients with sepsis in a Malaysian intensive care unit (Article)

 Abdul-Aziz, M.H.^{a,b}, Abd Rahman, A.N.^{bc}, Mat-Nor, M.-B.^d, Sulaiman, H.^e, Wallis, S.C.^a, Lipman, J.^{af}, Roberts, J.A.^{af}, Staatz, C.E.^{g,h}
^a Burns, Trauma, and Critical Care Research Centre, University of Queensland, Brisbane, Australia

^b School of Pharmacy, International Islamic University of Malaysia, Kuantan, Pahang, Malaysia

^c School of Pharmacy, University of Queensland, Brisbane, Australia

[View additional affiliations](#)
[View references \(53\)](#)

Abstract

Doripenem has been recently introduced in Malaysia and is used for severe infections in the intensive care unit. However, limited data currently exist to guide optimal dosing in this scenario. We aimed to describe the population pharmacokinetics of doripenem in Malaysian critically ill patients with sepsis and use Monte Carlo dosing simulations to develop clinically relevant dosing guidelines for these patients. In this pharmacokinetic study, 12 critically ill adult patients with sepsis receiving 500 mg of doripenem every 8 h as a 1-hour infusion were enrolled. Serial blood samples were collected on 2 different days, and population pharmacokinetic analysis was performed using a nonlinear mixed-effects modeling approach. A two-compartment linear model with between-subject and between-occasion variability on clearance was adequate in describing the data. The typical volume of distribution and clearance of doripenem in this cohort were 0.47 liters/kg and 0.14 liters/kg/h, respectively. Doripenem clearance was significantly influenced by patients' creatinine clearance (CL_{CR}), such that a 30-ml/min increase in the estimated CL_{CR} would increase doripenem CL by 52%. Monte Carlo dosing simulations suggested that, for pathogens with a MIC of 8 mg/liter, a dose of 1,000 mg every 8 h as a 1-hour infusion is optimal for patients with a CL_{CR} of 30 to 100 ml/min, while a dose of 2,000 mg every 8 h as a 4-h infusion is best for patients manifesting a CL_{CR} of >100 ml/min. Findings from this study suggest that, for doripenem usage in Malaysian critically ill patients, an alternative dosing approach may be meritorious, particularly when multidrug resistance pathogens are involved. Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Indexed keywords

EMTREE drug terms: doripenem

EMTREE medical terms: adult; aged; Article; blood sampling; central volume of distribution; clinical article; cohort analysis; creatinine clearance; critically ill patient; drug clearance; female; human; intensive care unit; Malaysian; male; middle aged; minimum inhibitory concentration; Monte Carlo method; multidrug resistance; open study; peripheral volume of distribution; practice guideline; priority journal; prospective study; sepsis; ventilator associated pneumonia; volume of distribution; young adult

Chemicals and CAS Registry Numbers: doripenem, 148016-81-3

Drug tradename: doribax, Janssen Cilag, United States; doribax, Raritan, United States.

Manufacturers: Drug manufacturer: Janssen Cilag, United States; Raritan, United States.

ISSN: 0096-4804 CODEN: AMACC Source Type: Journal Original language: English

DOI: 10.1128/AAC.01543-15 Document Type: Article

Publisher: American Society for Microbiology

References (53)

[View in search results format](#)

Cited by 0 documents

Inform me when this document is cited in Scopus:

[Set citation alert](#) | [Set citation feed](#)

Related documents

Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit | Farmacocinética de doripenem en pacientes con infecciones tratadas en y fuera de una unidad de cuidados intensivos

 Bhalodi, A.A., Keel, R.A., Quintiliani, R. (2013) *Annals of Pharmacotherapy*

Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration

 Roberts, J.A., Udy, A.A., Bullitta, J.B. (2014) *Journal of Antimicrobial Chemotherapy*

Standard versus prolonged doripenem infusion for treatment of gram-negative infections

 Hsai, L., Murray, K.P., Kokoska, L. (2013) *Annals of Pharmacotherapy*
[View all related documents based on references](#)

Find more related documents in Scopus based on:

[Authors](#) | [Keywords](#)